(Q44590334)

4 December 2017

title

The binding of HIV-1 protease inhibitors to human serum proteins (English)

1 reference

4 December 2017

1 reference

https://api.crossref.org/works/10.1016/S0301-4622(03)00071-1

12 March 2024

1 reference

https://api.crossref.org/works/10.1016/S0301-4622(03)00071-1

12 March 2024

1 reference

https://api.crossref.org/works/10.1016/S0301-4622(03)00071-1

12 March 2024

author name string

Arne Schön

1

1 reference

4 December 2017

Maria del Mar Ingaramo

2

1 reference

4 December 2017

Ernesto Freire

3

1 reference

4 December 2017

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=14499894

12 March 2024

publication date

1 September 2003

1 reference

full work available at URL

4 December 2017

https://api.elsevier.com/content/article/PII:S0301462203000711?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/S0301-4622(03)00071-1

https://api.elsevier.com/content/article/PII:S0301462203000711?httpAccept=text/plain

12 March 2024

1 reference

https://api.crossref.org/works/10.1016/S0301-4622(03)00071-1

12 March 2024

published in

Biophysical Chemistry

1 reference

4 December 2017

volume

105

1 reference

4 December 2017

issue

2-3

1 reference

4 December 2017

page(s)

221-230

1 reference

Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy

4 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0301-4622%2803%2900071-1

7 January 2021

Oral absorption of the HIV protease inhibitors: a current update

1 reference

https://api.crossref.org/works/10.1016%2FS0301-4622%2803%2900071-1

7 January 2021

Human alpha-1-glycoprotein and its interactions with drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0301-4622%2803%2900071-1

7 January 2021

The binding energetics of first- and second-generation HIV-1 protease inhibitors: implications for drug design

1 reference

https://api.crossref.org/works/10.1016%2FS0301-4622%2803%2900071-1

7 January 2021

Isolation and purification of alpha-1-acid glycoprotein from human liver

1 reference

https://api.crossref.org/works/10.1016%2FS0301-4622%2803%2900071-1

7 January 2021

How to measure and predict the molar absorption coefficient of a protein

1 reference

https://api.crossref.org/works/10.1016%2FS0301-4622%2803%2900071-1

7 January 2021

Anion-induced refolding of human serum albumin under low pH conditions

1 reference

https://api.crossref.org/works/10.1016%2FS0301-4622%2803%2900071-1

7 January 2021

Thermodynamic Basis of Resistance to HIV-1 Protease Inhibition: Calorimetric Analysis of the V82F/I84V Active Site Resistant Mutant†

1 reference

https://api.crossref.org/works/10.1016%2FS0301-4622%2803%2900071-1

7 January 2021

The structural stability of the HIV-1 protease

1 reference

https://api.crossref.org/works/10.1016%2FS0301-4622%2803%2900071-1

7 January 2021

The effect of inhibitor binding on the structural stability and cooperativity of the HIV-1 protease.

1 reference

https://api.crossref.org/works/10.1016%2FS0301-4622%2803%2900071-1

7 January 2021

Evidence for differences in the binding of drugs to the two main genetic variants of human alpha 1-acid glycoprotein

1 reference

https://api.crossref.org/works/10.1016%2FS0301-4622%2803%2900071-1

7 January 2021

Enantioselective binding of propranolol, disopyramide, and verapamil to human alpha(1)-acid glycoprotein

1 reference

https://api.crossref.org/works/10.1016%2FS0301-4622%2803%2900071-1

7 January 2021

Catalytic efficiency and vitality of HIV-1 proteases from African viral subtypes

1 reference

https://api.crossref.org/works/10.1016%2FS0301-4622%2803%2900071-1

7 January 2021

Plasma viral load, CD4+ cell counts, and HIV-1 production by cells

1 reference

https://api.crossref.org/works/10.1016%2FS0301-4622%2803%2900071-1

7 January 2021

Phosphorylation of 3'-azido-3'-deoxythymidine and selective interaction of the 5'-triphosphate with human immunodeficiency virus reverse transcriptase

1 reference

https://api.crossref.org/works/10.1016%2FS0301-4622%2803%2900071-1

7 January 2021

Human serum attenuates the activity of protease inhibitors toward wild-type and mutant human immunodeficiency virus

1 reference

https://api.crossref.org/works/10.1016%2FS0301-4622%2803%2900071-1

7 January 2021

Resistance to HIV protease inhibitors: a comparison of enzyme inhibition and antiviral potency

1 reference

https://api.crossref.org/works/10.1016%2FS0301-4622%2803%2900071-1

7 January 2021

Counteracting HIV-1 protease drug resistance: structural analysis of mutant proteases complexed with XV638 and SD146, cyclic urea amides with broad specificities

1 reference

https://api.crossref.org/works/10.1016%2FS0301-4622%2803%2900071-1

7 January 2021

Importance of protease inhibitor plasma levels in HIV-infected patients treated with genotypic-guided therapy: pharmacological data from the Viradapt Study

1 reference

https://api.crossref.org/works/10.1016%2FS0301-4622%2803%2900071-1

7 January 2021

Structure-based prediction of binding affinities and molecular design of peptide ligands.

1 reference

https://api.crossref.org/works/10.1016%2FS0301-4622%2803%2900071-1

7 January 2021

Structural parameterization of the binding enthalpy of small ligands

1 reference

https://api.crossref.org/works/10.1016%2FS0301-4622%2803%2900071-1

7 January 2021

Drug binding to human alpha-1-acid glycoprotein in health and disease

5

1 reference

https://api.crossref.org/works/10.1016/S0301-4622(03)00071-1

12 March 2024

Identifiers

1 reference

4 December 2017

1 reference